

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/063984 A1

(51) International Patent Classification:

C07K 16/24 (2006.01) A61K 39/395 (2006.01)
C07K 16/28 (2006.01) A61P 11/06 (2006.01)
C07K 16/18 (2006.01) A61P 37/08 (2006.01)
C12N 15/62 (2006.01)

(21) International Application Number:

PCT/EP2021/076356

(22) International Filing Date:

24 September 2021 (24.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/083,222 25 September 2020 (25.09.2020) US
20315421.6 28 September 2020 (28.09.2020) EP
20306115.5 29 September 2020 (29.09.2020) EP
63/093,804 20 October 2020 (20.10.2020) US

(71) Applicants: **ABLYNX NV** [BE/BE]; Technologiepark 21,
9052 Zwijnaarde (BE). **SANOFI** [FR/FR]; 54 rue La
Boétie, 75008 Paris (FR).

(72) Inventors: **ROMMELAERE, Heidi**; c/o Ablynx N.V.,
Patent Department, Technologiepark 21, 9052 Zwijnaarde
(BE). **BRIGÉ, Ann**; c/o Ablynx N.V., Patent Depart-
ment, Technologiepark 21, 9052 Zwijnaarde (BE). **COR-
NELIS, Sigrid**; c/o Ablynx N.V., Patent Department, Tech-
nologiepark 21, 9052 Zwijnaarde (BE). **DOMBRECHT,
Bruno**; c/o Ablynx N.V., Patent Department, Technolo-
giepark 21, 9052 Zwijnaarde (BE). **ERB, Klaus**; c/o
Boehringer Ingelheim International, GmbH, Binger Strasse
173, 55216 Ingelheim am Rhein (DE). **LORENT, Eric**; c/
o Ablynx N.V., Patent Department, Technologiepark 21,
9052 Zwijnaarde (BE). **PARK, John**; c/o Boehringer Ingel-
heim International, GmbH, Binger Strasse 173, 55216 Ingel-
heim am Rhein (DE). **RESNICK, Robert**; c/o Sanofi,
55 Corporate Drive, Bridgewater, New Jersey 08807 (US).
RIEGER, Melanie; c/o Ablynx N.V., Patent Department,
Technologiepark 21, 9052 Zwijnaarde (BE). **WEIGLE,
Bernd**; c/o Boehringer Ingelheim International, GmbH,
Binger Strasse 173, 55216 Ingelheim am Rhein (DE).

(74) Agent: **HOFFMANN EITLE PATENT- UND
RECHTSANWÄLTE PARTMBB, ASSOCIATION
NO. 151**; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND OX40L

(57) Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.

WO 2022/063984 A1